CA3148592A1 - Selective estrogen receptor degrader - Google Patents

Selective estrogen receptor degrader Download PDF

Info

Publication number
CA3148592A1
CA3148592A1 CA3148592A CA3148592A CA3148592A1 CA 3148592 A1 CA3148592 A1 CA 3148592A1 CA 3148592 A CA3148592 A CA 3148592A CA 3148592 A CA3148592 A CA 3148592A CA 3148592 A1 CA3148592 A1 CA 3148592A1
Authority
CA
Canada
Prior art keywords
compound
formula
cancer
less
chromen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3148592A
Other languages
English (en)
French (fr)
Inventor
Ranjan Kumar Pal
Biswajit Samanta
Jayraj Dilipbhai Aradhye
Sandeep Pankajkumar PATHAK
Kaushik Dhanjibhai PRAJAPATI
Bhavesh Mohanbhai Panchal
Trinadha Rao Chitturi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of CA3148592A1 publication Critical patent/CA3148592A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3148592A 2019-07-22 2020-07-22 Selective estrogen receptor degrader Pending CA3148592A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
CA3148592A1 true CA3148592A1 (en) 2021-01-28

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3148592A Pending CA3148592A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Country Status (15)

Country Link
US (2) US11014915B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003525A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541938A (cg-RX-API-DMAC7.html)
KR (1) KR20220046586A (cg-RX-API-DMAC7.html)
CN (1) CN114302879A (cg-RX-API-DMAC7.html)
AU (1) AU2020317099A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148592A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000156A1 (cg-RX-API-DMAC7.html)
IL (1) IL290036A (cg-RX-API-DMAC7.html)
MX (1) MX2022001013A (cg-RX-API-DMAC7.html)
PE (1) PE20221588A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201157B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) * 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
US12391667B2 (en) 2019-07-22 2025-08-19 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
US10865199B2 (en) * 2015-10-27 2020-12-15 Sun Pharma Advanced Research Company Limited Heterocyclic antiestrogens
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
BR112022001285A2 (pt) 2022-03-22
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
MX2022001013A (es) 2022-02-22
US20210261534A1 (en) 2021-08-26
KR20220046586A (ko) 2022-04-14
US20210024504A1 (en) 2021-01-28
IL290036A (en) 2022-03-01
CN114302879A (zh) 2022-04-08
AU2020317099A1 (en) 2022-02-24
PH12022550182A1 (en) 2022-11-14
US11014915B2 (en) 2021-05-25
EP4003525A1 (en) 2022-06-01
CL2022000156A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
US11014915B2 (en) Selective estrogen receptor degrader
US20240226073A9 (en) TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
CN1181077A (zh) 苯并吡喃类化合物及其使用方法
CZ299721B6 (cs) Lécivo pro lécení mocové inkontinence
CN107406433A (zh) 用于治疗癌症的2,3‑二苯基色烯的衍生物
CN105324115A (zh) 雌激素受体调节剂及其用途
US20020072538A1 (en) NMDA NR2B antagonists for treatment
US20040110791A1 (en) Novel arylaminopropane analogues and their use for the treatment of glaucoma
Halama et al. Improved process for the preparation of Montelukast: development of an efficient synthesis, identification of critical impurities and degradants
TW202132294A (zh) 雌激素受體調節劑之鹽及形式
US20080085930A1 (en) Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
TW202300492A (zh) 選擇性雌激素受體降解劑
US7655653B2 (en) Tetrahydrobenzfluorene derivatives
WO2004031125A1 (ja) スピロ化合物、それを含有する医薬組成物及び該化合物の中間体
JP3294574B2 (ja) 光学的に純粋なアンドロゲンメディエーター
RU2855858C2 (ru) ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
WO2025255358A1 (en) Solid forms of posiphen d-tartrate and processes of preparation thereof
CN101134739A (zh) 新的β-内酰胺类化合物及其制备方法及其药物用途
HK40056233A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
US20100009949A1 (en) Novel method
HK1214532B (en) Estrogen receptor modulator and uses thereof
HK1124337A (en) Nuclear receptor binding agents

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260204

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260309

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703